Investor Relations
Selecta Biosciences is committed to solving the challenges associated with unwanted immunogenicity through our clinically-validated ImmTOR® precision immune tolerance platform. The potentially broad applicability of ImmTOR® gives us the opportunity to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.